Large Inflow of Money Witnessed in Boston Scientific Corporation

Boston Scientific Corporation (BSX) : Investors lapped up stocks on upticks to the tune of $21.45 million in the Thursdays trading session. The trading value on downticks was comparatively at $16.23 million and the uptick to downtick ratio of 1.32 indicates continuous buying by the bulls. The net money flow into the stock was $5.22 million. The block trades were dominated by the bulls with a healthy 7.49, uptick to downtick ratio. Only $1.1 million worth of trades exchanged hands on downticks showing the reluctance of the large traders to part with their holdings. Upticks saw transactions worth $8.25 clearly indicating buying by large investors. The total money flow for block trades stood at $7.15 million, which is a positive for the stock in the long-term. Boston Scientific Corporation (BSX) fell $0.01 during the day at $23.66, a drop of -0.04% over the previous days close. However, for the week, the stock is 1.07%, compared to the previous week.


Boston Scientific Corporation (BSX) : The highest level Boston Scientific Corporation (BSX) is projected to reach is $28 for the short term and the lowest estimate is at $20. The consolidated price target from 19 rating analysts who initiate coverage on the stock is $23.95 and the possibility the share price can swing is $2.27. The stock has recorded a 20-day Moving Average of 3.35% and the 50-Day Moving Average is 5.23%.

Boston Scientific Corporation (NYSE:BSX): The stock opened at $23.67 on Thursday but the bulls could not build on the opening and the stock topped out at $23.80 for the day. The stock traded down to $23.54 during the day, due to lack of any buying support eventually closed down at $23.66 with a loss of -0.04% for the day. The stock had closed at $23.67 on the previous day. The total traded volume was 7,007,514 shares.

Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.